003090.KS
Daewoong Co., Ltd.
KSC · Healthcare · Drug Manufacturers - General · KR
KRW 17,200.00
−1.43%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2122.3B | 2068.6B | 1936.9B | 1815.1B | 1697.3B |
| Cost of Revenue | 1012.9B | 977.4B | 888.0B | 883.9B | 797.7B |
| Gross Profit | 1109.1B | 1091.0B | 1048.9B | 931.2B | 899.7B |
| Operating Expenses | |||||
| R&D Expense | 193.9B | 186.7B | 176.0B | 176.6B | 169.9B |
| SG&A Expense | 522.4B | 452.4B | 400.7B | 375.7B | 341.2B |
| General & Admin Expense | 106.2B | 38.0B | 28.2B | 27.1B | 25.3B |
| Selling & Marketing Expense | 445.7B | 414.5B | 372.5B | 348.5B | 315.9B |
| Other Expenses | 203.6B | 191.3B | 190.2B | 183.4B | 181.2B |
| Total Operating Expenses | 869.4B | 830.4B | 767.0B | 735.6B | 692.3B |
| Cost and Expenses | 1882.3B | 1806.6B | 1655.0B | 1619.2B | 1490.0B |
| Operating Income (EBIT) | 239.7B | 260.5B | 281.9B | 195.9B | 207.3B |
| Non-Operating | |||||
| Interest Income | 6.7B | 6.2B | 9.2B | 9.3B | 11.4B |
| Interest Expense | 16.2B | 13.9B | 7.6B | 14.0B | 8.4B |
| Net Interest Income | (9.5B) | (7.6B) | 1.6B | (4.7B) | 3.1B |
| Other Non-Op Income/Expense | (1.5B) | (16.9B) | (166.1B) | 6.6B | (52.4B) |
| Non-Operating Income (excl Interest) | (21.9B) | 4.3B | 158.6B | (20.6B) | 44.0B |
| EBT (Pre-Tax Income) | 238.2B | 244.6B | 115.8B | 202.5B | 154.9B |
| Income Tax Expense | 16.6B | 15.7B | 46.9B | 11.1B | 34.7B |
| Bottom Line | |||||
| Net Income | 179.4B | 175.1B | 57.9B | 152.7B | 102.6B |
| Earnings from Cont. Ops | 221.7B | 227.9B | 68.9B | 191.4B | 120.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 179.4B | 175.1B | 57.9B | 152.7B | 102.6B |
| Per Share | |||||
| Basic EPS | ₩4,647 | ₩4,280 | ₩1,416 | ₩3,692 | ₩2,467 |
| Diluted EPS | ₩4,647 | ₩4,280 | ₩1,416 | ₩3,692 | ₩2,467 |
| Revenue Per Share | ₩50,486 | ₩35,579 | ₩47,386 | ₩43,892 | ₩40,824 |
| Shares | |||||
| Basic Shares Outstanding | 42.0M | 58.1M | 40.9M | 41.4M | 41.6M |
| Diluted Shares Outstanding | 42.0M | 58.1M | 40.9M | 41.4M | 41.6M |
| Profitability Metrics | |||||
| EBITDA | 334.2B | 323.4B | 182.1B | 270.3B | 211.4B |
| D&A | 82.5B | 62.9B | 58.8B | 54.2B | 48.1B |
| EBIT | 251.8B | 260.5B | 123.3B | 216.5B | 163.3B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026